[Anticoagulation and antiaggregation in cardiac patients].

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Aspirin is beneficial for primary prevention of coronary events at high risk.
• Aspirin and clopidogrel reduce cardiovascular events in coronary disease patients.
• Combining aspirin with clopidogrel offers additional event reduction but increases bleeding risk.

Purpose of the Study:

• To review current recommendations for preventing thromboembolic events and bleeding complications.
• To outline recommended antithrombotic therapy intensity.
• To summarize key guidelines for managing atrial fibrillation patients.

Main Methods:

• Review of recent studies on myocardial infarction treatments.
• Analysis of risks associated with therapeutic anticoagulation.
• Synthesis of guidelines for valvular heart disease and prosthetic valve management.

Main Results:

• Aspirin is safe and effective for primary prevention with an annual coronary event risk of 1.5% or higher.
• Combined aspirin and clopidogrel reduce cardiovascular events but increase bleeding risk.
• Coumadin-based therapies show comparable effectiveness to aspirin alone in myocardial infarction patients.

Conclusions:

• Antithrombotic therapy requires careful balancing of efficacy and bleeding risk.
• Specific guidelines are crucial for managing patients with atrial fibrillation and valvular heart disease.
• Optimized antithrombotic strategies are essential for preventing thromboembolic and bleeding complications.